Altamira Therapeutics Ltd. CYTOF
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -42.27% | 58.04% | -- |
| Total Depreciation and Amortization | -- | -- | 94.19% | -3.79% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 100.42% | -81.36% | -- |
| Change in Net Operating Assets | -- | -- | 100.78% | 108.95% | -- |
| Cash from Operations | -- | -- | 27.49% | 54.06% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -6,200.00% | 98.30% | -- |
| Cash from Investing | -- | -- | -57,800.00% | 83.15% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 19.98% | 48.91% | -- |
| Issuance of Common Stock | -- | -- | 22.35% | -32.18% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -301.21% | -89.17% | -- |
| Cash from Financing | -- | -- | -22.68% | -55.94% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -120.14% | -88.69% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 582.99% | 2.66% | -- |